HBV, HCV
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases worldwide. The two viruses share same modes of transmission, coinfection is not uncommon, especially among high risk populations.
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper elimination targets. Therefore, we estimated HCV reinfection rates among DAA-treated individuals, including PWID.
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study
People who inject drugs (PWID) are often excluded from HCV treatment programs due to concerns about their ability to adhere to care. Georgia has a high prevalence of HCV infection (5.4% of chronic cases in general population) with an epidemic concentrated among PWID. We evaluated adherence to care and sustained virologic response (SVR) among PWID in Georgia.
Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Alastair Heffernan et al.
We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO’s elimination targets could be met.
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. M. Hellard et al.
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4
Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis
The research team compiled deidentified questions during field enrollments. Results. FAQs were reviewed and categorized into four major domains, including risk/prevention, screening, treatment, and reinfection. FAQs were addressed by a team of medical and public health professionals, using the most current research and recommendations.
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients, Maria P. Carrieri, et al.
Coffee has anti-inflammatory and hepatoprotective properties but its effect on mortality risk has never been investigated in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study shows that elevated coffee consumption (≥3 cups/day) halves all-cause mortality risk in patients co-infected with HIV-HCV. The benefits of coffee extracts and supplementing dietary intake with other anti-inflammatory compounds need to be evaluated in this population.
Hepatitis C Virus Diagnosis and the Holy Grail
It is not often the world has the opportunity to turn a public health crisis into a good news story. The development of oral, highly effective, pangenotypic direct-acting antivirals (DAAs) has now paved the way to cure the 71 million people estimated to be living with chronic hepatitis C virus (HCV) infection globally. This report highlights improving access to rapid, simple, and affordable HCV diagnostics is critical to achieve global HCV elimination.
EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities
The increasing health burden, the advent of novel and costly therapies, and the changing epidemiology demand innovative approaches and solutions for patients with liver diseases in European countries, which also face major demographic changes. By working with governmental and non-governmental organisations, such strategies must overcome cultural, ethical, and lifestyle barriers to vaccines and other preventive measures for obesity and alcohol consumption. F
